A Phase 1, Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Subcutaneous Injection of MLN1202 in the Japanese and Caucasian Healthy Male Participants
Overview
- Phase
- Phase 1
- Intervention
- MLN1202
- Conditions
- Healthy Japanese and Caucasian Male Adults
- Sponsor
- Takeda
- Primary Endpoint
- Number of Participants Reporting One or More Treatment-emergent Adverse Events
- Status
- Withdrawn
- Last Updated
- 9 years ago
Overview
Brief Summary
The objective of the study is to investigate the safety, pharmacokinetics, and pharmacodynamic effect of a single dose of MLN1202 in healthy Japanese male adults.
Detailed Description
This is a single dose, phase 1 study in healthy Japanese and Caucasian male adults. Japanese subjects will be assigned to Cohort J1 (at a dose of 75 mg), Cohort J2 (105 mg), Cohort J3 (150 mg), or Cohort J4 (450 mg) in a randomized, double-blind, placebo-controlled manner, while Caucasian subjects to Cohort C1 (at a dose of 75 mg) or Cohort C2 (150 mg) in an open-label manner. Takeda has made a business decision to terminate this study due to portfolio re-prioritization. There were no safety or efficacy concerns.
Investigators
Eligibility Criteria
Inclusion Criteria
- •In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
- •The participant signs and dates a written informed consent form (ICF) prior to the initiation of any study procedures.
- •The participant is a healthy adult man who is defined as Japanese (all parents and grandparents of the participant are Japanese) or Caucasian (all parents and grandparents of the participant are Caucasian).
- •The participant is between 20 and 45 years of age at the time of informed consent.
- •The participant has a body weight of at least 50 kg and has a body mass index (BMI) between 18.5 and 25.0 kg /m2 when the participant is Japanese or between 18.5 and 30.0 kg /m2 when the participant is Caucasian at the time of screening and baseline examination.
- •A male participant who is sexually active with a female partner of childbearing potential and who has not received contraceptive therapy agrees to use adequate contraception from the time of informed consent until 12 weeks (84 days) after administration of the study drug.
Exclusion Criteria
- •The participant has received any other investigational compound within 16 weeks (112 days) prior to administration of the study drug.
- •The participant has previously received agents containing MLN1202, a monoclonal antibody or monoclonal antibody fragment.
- •The participant has been vaccinated within 4 weeks (28 days) prior to administration of the study drug or is planning to be vaccinated during the study period.
- •The participant is a study site employee or immediate family member of the employee, or may consent under duress.
- •The participant has poorly-controlled, clinically significant neurologic, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, or endocrine disease, hemorrhagic disorder or other abnormalities which may impact the ability of the participant to participate or potentially confound the study results.
- •The participant has recurrent serious or poorly-controlled infection and is considered to have difficulty participating in the study by the investigator.
- •The participant has a history of hypersensitivity or allergies to MLN1202 or additives contained in MLN1202 preparations.
- •The participant has a history of hypersensitivity or allergies to monoclonal antibodies other than MLN
- •The participant has positive results in urine drug tests at screening.
- •The participant has a history of drug abuse (defined as any illicit drug use) or a history of alcohol dependence within 2 years prior to the study visit at screening or is unwilling to agree to abstain from alcohol and drugs throughout the study period.
Arms & Interventions
Cohort J3: MLN1202 (150 mg)
Single subcutaneous administration of MLN1202 (150 mg) in 6 healthy Japanese male adults
Intervention: MLN1202
Cohort J1: MLN1202 (75 mg)
Single subcutaneous administration of MLN1202 (75 mg) in 6 healthy Japanese male adults
Intervention: MLN1202
Cohort J1: placebo
Single subcutaneous administration of placebo in 2 healthy Japanese male adults
Intervention: MLN1202 Placebo
Cohort J2:MLN1202 (105 mg)
Single subcutaneous administration of MLN1202 (105 mg) in 6 healthy Japanese male adults
Intervention: MLN1202
Cohort J2: placebo
Single subcutaneous administration of placebo in 2 healthy Japanese male adults
Intervention: MLN1202 Placebo
Cohort J3: placebo
Single subcutaneous administration of placebo in 2 healthy Japanese male adults
Intervention: MLN1202 Placebo
Cohort J4: MLN1202 (450 mg)
Single subcutaneous administration of MLN1202 (450 mg) in 6 healthy Japanese male adults
Intervention: MLN1202
Cohort J4: placebo
Single subcutaneous administration of placebo in 2 healthy Japanese male adults
Intervention: MLN1202 Placebo
Cohort C1: MLN1202 (75 mg)
Single subcutaneous administration of MLN1202 (75 mg) in healthy Causacian male adults
Intervention: MLN1202
Cohort C2: MLN1202 (150 mg)
Single subcutaneous administration of MLN1202 (150 mg) in healthy Causacian male adults
Intervention: MLN1202
Outcomes
Primary Outcomes
Number of Participants Reporting One or More Treatment-emergent Adverse Events
Time Frame: Up to Day 37
The adverse event is defined as any unfavorable and unintended sign, symptom, or disease that develops when a drug is administered, irrespective of the causal relationship to the drug.
Secondary Outcomes
- Maximum observed serum concentration (Cmax) of MLN1202(Up to Day 37)
- Area under the serum concentration-time curve (AUC) of MLN1202 in serum(Up to Day 37)
- Changes in serum monocyte chemoattractant protein-1 (MCP-1) concentrations(Up to Day 37)
- Changes in monocyte count from baseline(Up to Day 37)